Navigation Links
Modulation in Biological Technology

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... in" of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug. ... to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic ... of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the ...

Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units

... new RapidBlue(TM) endovascular temperature modulation system. This new system automatically cools or ... InnerCool's CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable ... of InnerCool's endovascular temperature modulation therapy as an adjunctive treatment for ...

Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System

... RapidBlue(TM) System, an endovascular temperature modulation device. InnerCool's RapidBlue System is a ... for high-performance endovascular temperature modulation includes a programmable console with an ... InnerCool's CoolBlue surface temperature modulation system, which includes a console and a disposable ...

Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification

... the most dynamic and best-in-class temperature modulation system on the market and receiving CE Mark and UL ... for high-performance endovascular temperature modulation includes a programmable console with an ... InnerCool's CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable ...

Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems

... and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market ... hospital where we focus are utilizing temperature modulation products and therapies." InnerCool's Surface and Endovascular Temperature modulation Systems InnerCool's new CoolBlue(TM) surface ...

Cardium Reports on First Quarter 2008 Highlights and Financial Results

... for InnerCool's CoolBlue(TM) surface temperature modulation system and RapidBlue endovascular system. ... for InnerCool's portfolio of temperature modulation systems. -- Australian distribution ... CoolBlue and RapidBlue temperature modulation systems in Australia and New Zealand. -- ...

Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University

... patient with InnerCool's endovascular temperature modulation system. "InnerCool's endovascular systems are ... and ischemic brain damage. Patient temperature modulation is a rapidly-advancing field focused ... outcomes. InnerCool's Patient Temperature modulation Systems InnerCool's endovascular approach to ...

Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems

... for InnerCool's portfolio of temperature modulation systems. This agreement covers InnerCool's ... and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market ... growth of InnerCool's temperature modulation business in an efficient and cost-effective ...

Cardium Announces Retirement of Director

... medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell ... so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be ...

International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool System

... medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell ... so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be ...

Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study

... medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell ... so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be ...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

... acute myeloid leukemia and suppression of solid tumor growth and biomarker modulation in models of prostate adenocarcinoma and non-Hodgkin's lymphoma. In ... can induce progression of the cell cycle, inhibition of apoptosis, and modulation of other signal transduction pathways. Transformation of Pim kinase in ...

Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries

... our platform technology and expertise in the growing field of temperature modulation therapy," added Reinhard. "These new products, like UroCool, are being ... medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell ...

Peptimmune Presentations at Upcoming Events

... for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby ... shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and ...

Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis

... for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby ... shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and ...

PTC124 Featured at Third Annual Congress of Myology

... therapeutic intervention in a broad range of genetic disorders through the modulation of protein levels. "We are pleased to have the opportunity to share our ... drug discovery and development activities, including the Gene Expression modulation by Small-molecules (GEMS) technology platform, which has been the basis ...

Peptimmune Announces First Close of Series D Private Financing

... class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the ... shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and ...

Amarin Signs Agreement to Acquire Ester Neurosciences

... conditions. The basic premise of Ester's therapeutic paradigm is the modulation of the "read-through" isoform of acetylcholinesterase ("AChE-R"), an ... an indirect inhibitory effect on key pro-inflammatory cytokines via modulation of AChE-R, as well as a direct anti-inflammatory effect via modulation of ...

Anavex advances drug candidate for treatment of Alzheimer's disease

... any known receptor class. In the CNS, they are involved in the modulation of neurotransmitter receptor function, neurotransmitter release and ... non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. ANAVEX's ...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

... production of the protein vascular endothelial growth factor (VEGF) in tumors. PTC discovered PTC299 through PTC's proprietary GEMS (Gene Expression modulation by Small-Molecules) technology by targeting the post-transcriptional processes that regulate VEGF formation. Overexpression of VEGF plays a key role ...

Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips Electronics

... will be completed in the time frame expected by the parties, or at all, the acquisition will effectively accelerate InnerCool's patient temperature modulation business or expand its market, that product modifications or launches will be successful or that the resulting products will be favorably received in ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... response. These results were obtained for L.E.A.P.S. vaccines against herpes simplex and HIV. The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

PTC Therapeutics Receives $2.6 Million in Government Grants

... of the protein vascular endothelial growth factor, or VEGF, in tumors. PTC discovered PTC299 through PTC's proprietary GEMS (Gene Expression modulation by Small-Molecules) technology by targeting the post-transcriptional processes that regulate VEGF formation. Overexpression of VEGF plays a key role ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... mutations by focusing on more conserved and common epitopes critical for critical viral function. The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program

... indications. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... characterized by involuntary bodily movements as seen in patients suffering from tardive dyskinesia, and Huntington's disease. Additionally, the modulation of dopamine pathways may also be useful for patients suffering from schizophrenia. The pre-clinical IND enabling studies have been completed and ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... protective epitopes from two different essential proteins common to all influenza A virus strains. L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

... is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex' first in class products show promise for the safe and effective treatment of a broad spectrum of serious ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... arthritis, since these cytokines cause much of the damage seen in rheumatoid arthritis patients." L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug

... done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often ...

Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board

... to working closely with him as we move the company forward." About N30 Pharma N30 Pharma is a cardiopulmonary medicine company focused on the modulation of endogenous Nitric Oxide bioavailability using targeted novel small molecule drugs. The company is headquartered in Boulder, Colorado and New York ...

Cardium Completes $3.5 Million Credit Facility

... indications. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine

... indications. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

... patent coverage for the therapeutic use of antisense compounds targeting apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense modulation of apolipoprotein B expression" -- Initiated a Phase 1 study of ISIS 353512, an antisense drug that targets C-reactive protein Other Drug ...

SuperGen Reports 2008 Third Quarter Financial Results

... kinase inhibitor targeting Rad51 is not toxic to human primary marrow stem cells at clinically relevant concentrations. -- Abstract 571: modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a small molecule JAK2 inhibitor. Conference Call Information SuperGen will host ...

Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.

... is a biotechnology company developing novel therapies for patients and doctors providing more targeted and safer clinical solutions for immune modulation and related therapies. The company recently closed its Series A round and intends to commercialize its lead therapeutic agent TOL101 (T-cell ...

SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy

... tyrosine kinase inhibitor targeting Rad51 is not toxic to human primary marrow stem cells at clinically relevant concentrations Abstract 571: modulation of JAK2 signaling pathways in vitro and in vivo Copies of the 20th EORTC-NCI-AACR Symposium poster presentations will be available in the pipeline ...

SuperGen to Present Data at EORTC-NCI-AACR

... to human primary marrow stem cells at clinically relevant concentrations Oct 24 Abstract 571: modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor ...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

... control processes and has developed proprietary technologies that it applies in its drug discovery activities, including the Gene Expression modulation by Small-molecules (GEMS) technology, which has been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, ...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

... -- Granted broad patent coverage for antisense compounds targeting apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense modulation of Apolipoprotein B Expression" Metabolic Program -- Highlighted our robust diabetes and obesity portfolio with nine presentations and ...
Other Contents
(Date:11/21/2014)...  Earlier this year Donald Spector , Chairman ... of the most prolific inventors in the world, got ... Smartphones to third party agencies. Spector envisioned this technology ... the earliest known patents in this area. Now major ... child care, elder care and hospital applications. This technology ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:11/22/2014)... (HealthDay News) -- The wide variety and complexity of ... for people with food allergies, an expert warns. ... types of food allergies that it can be really ... Guha Krishnaswamy, director of allergy and clinical immunology at ... news release. "If you know you have food ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
Other TagsOther Tags